Future Research on Subarachnoid Hemorrhage: Guilherme Dabus, MD
The codirector of interventional neuroradiology and vice-chief of the department of neuroscience at Baptist Health Miami Neuroscience Institute discussed the questions that still remain with identifying and treating subarachnoid hemorrhage. [WATCH TIME: 3 minutes]
Clinical Viewpoint on Newly Approved Combination Therapy for Pompe Disease: Barry J. Byrne, MD, PhD
The chief medical advisor at the Muscular Dystrophy Association gave his reaction to Amicus Pharmaceuticals’ recently FDA approved 2-part therapy for patients living with Pompe disease. [WATCH TIME: 7 minutes]
Unmet Needs and Future Considerations in Parkinson Disease
Robert Hauser, MD, MBA, discussed unmet needs and future consideration in Parkinson disease.
Amantadine Extended Release for the Management of Dyskinesia and OFF Episodes
Robert Hauser, MD, MBA, talks about amantadine extended release for management of dyskinesia and OFF episodes.
Treatment of OFF Time in Parkinson Disease
Robert Hauser, MD, MBA, shares his expertise in the treatment of OFF time in Parkinson disease.
The Effects of Depression in Parkinson Disease and Need for Mental Health Professionals: James Beck, PhD
The senior vice president and chief scientific officer of the Parkinson’s Foundation provided perspective on the reasons for the lack of mental health specialists in Parkinson disease care and the complexities behind treating depression. [WATCH TIME: 4 minutes]
Real-World Experience With Ofatumumab
Jason Freeman, MD, MBA, and James Stankiewicz, MD, discuss the poster “Real-World Experience With Ofatumumab” presented at ACTRIMS 2023.
Sponsored By Novartis.
Diving Into the Potential of Monoclonal Antibodies for Alzheimer Disease Treatment: Gayatri Devi, MD
The clinical professor of neurology at Lenox Hill Hospital/Northwell Health talked about her experience with monoclonal antibodies for Alzheimer disease treatment as well as the challenges and risks associated with them. [WATCH TIME: 8 minutes]
Emerging Trends That Challenge the Landscape of Care for Multiple Sclerosis: Stephen Krieger, MD
The associate professor of neurology at Icahn School of Medicine at Mount Sinai talked about the promising new treatments for multiple sclerosis, the significance of the spinal cord in the disease, and the use of artificial intelligence in neuroimaging. [WATCH TIME: 3 minutes]
Providing Optimal Management for Migraine Amid a Growing Treatment Landscape: Jessica Ailani, MD
The director of the MedStar Georgetown Headache Center discussed the importance of a healthy clinician-patient relationship and the conversations needed during treatment selection for migraine. [WATCH TIME: 4 minutes]
Exploring Synergistic Treatment Strategies for Migraine With Monoclonal Antibodies and Gepants: Stewart J Tepper, MD
The professor of neurology at the Geisel School of Medicine at Dartmouth talked about recent studies presented at the International Headache Congress on a potential migraine prevention treatment targeting pituitary adenylate cyclase activating polypeptide. [WATCH TIME: 5 minutes]
Quality of Life and Treatment Satisfaction With Disease-Modifying Therapies
Jason Freeman, MD, MBA, and Brandon Brown, PharmD, discuss the poster “Quality of Life and Treatment Satisfaction With Disease-Modifying Therapies in Multiple Sclerosis” presented at ACTRIMS 2023.
Sponsored By Novartis.
Treatment Decision Process for Subarachnoid Hemorrhage: Guilherme Dabus, MD
The codirector of interventional neuroradiology and vice-chief of the department of neuroscience at Baptist Health Miami Neuroscience Institute provided clarity on the complexities with treating subarachnoid hemorrhage on an individual case basis. [WATCH TIME: 4 minutes]
Championing Women's Leadership in Neurology: Jennifer Frontera, MD
The professor of neurology at NYU Langone Grossman School of Medicine discussed the Women in Neurology session she gave at IFN 2023, where women shared their experiences from their medical careers. [WATCH TIME: 3 minutes]
AdComm Committee Downvotes NurOwn, ADELY01 Cleared for Trials, Axsome Pushes Back SYMPHONY Trial
Neurology News Network for the week ending September 30, 2023. [WATCH TIME: 4 minutes]
Mechanistic Approach Behind AMX0035 in Progressive Supranuclear Palsy: Gunter Hoglinger, MD
The professor of neurology and translational neuroscientist at Ludwig-Maximillian’s University Munich detailed the logic behind the ORION study, a new trial assessing AMX0035, an approved therapy for ALS, in patients with progressive supranuclear palsy. [WATCH TIME: 4 minutes]
Recent Advances in Epilepsy Management: New Treatments and Innovative Procedures: Patricia C. Dugan, MD
The associate professor of neurology at NYU Grossman School of Medicine discussed her talk at IFN 2023 on advancements in epilepsy treatments, highlighting new medications and surgical options. [WATCH TIME: 3 minutes]
Adjusting Motor Fluctuation Management in an Era of Neuromodulation: Laxman Bahroo, DO
The professor of neurology and resident program director at MedStar Georgetown University Hospital discussed how Parkinson disease motor fluctuations are managed amid new, novel technologies incorporated in the field. [WATCH TIME: 4 minutes]
Immunoglobulins in Primary Progressive and Relapsing-Remitting Multiple Sclerosis
Jason Freeman, MD, MBA, and Shankar Sadasivan, PhD, discuss the poster “Immunoglobulins in Primary Progressive and Relapsing-Remitting Multiple Sclerosis” presented at ACTRIMS 2023.
Sponsored By Novartis.
Empowering Women to Develop Leadership Skills in Neurology: Lara V. Marcuse, MD
The codirector of the Mount Sinai Epilepsy Program at the Icahn School of Medicine at Mount Sinai talked about the Women in Neurology and Leadership session she spoke in at IFN 2023. [WATCH TIME: 3 minutes]
Future of gMG Treatment
James F. Howard Jr, MD, shares thoughts on the future of the treatment of gMG, highlighting the renewed interest in the disease landscape.
Other FcRn Targeting Agents gMG
An expert neurologist reviews efficacy and safety data of rozanolixizumab, an FcRn-targeting agent approved for treatment of gMG, as well as how it differs from efgartigimod.
Subcutaneous Efgartigimod for Treatment of gMG
James F. Howard Jr, MD, discusses both intravenous and subcutaneous efgartigimod for the treatment of gMG.
Perfecting a Cocktail of Approaches to Treat Alzheimer Disease: Richard Isaacson, MD
The director of the Center for Brain Health and Alzheimer Prevention Clinic at Florida Atlantic University provided perspectives on the multimodal, multitargeted approach needed to treat Alzheimer disease. [WATCH TIME: 5 minutes]
Predictability of Dyskinesia and OFF Episodes in Parkinson Disease
Robert Hauser, MD, MBA, reviews the predictability of dyskinesia and OFF episodes in Parkinson disease.
Defining the Patient Experience in Parkinson Disease
Robert Hauser, MD, MBA, discusses how the patient experience is defined in Parkinson disease.
Clinical Perspective on the Advances and Challenges in Multiple Sclerosis Treatment: Patricia K. Coyle, MD
The professor of neurology at Stony Brook University Medical Center discussed the progress observed in the field of multiple sclerosis and the lack of effective treatments for progressive forms of the disease. [WATCH TIME: 3 minutes]
Advancements in Stroke Care, Ischemic Stroke, and Cerebral Hemorrhages: Matthew Schrag, MD, PhD
The associate professor of neurology at Vanderbilt University Medical Center discussed the progress in stroke care, focusing on ischemic strokes and cerebral hemorrhages, and their connection with vascular diseases and cognitive disorders. [WATCH TIME: 3 minutes]
The Complex Landscape of NMOSD and MOGAD-Associated Diseases: Erin Longbrake, MD, PhD
The associate professor of neurology at Yale School of Medicine discussed the differentiation of neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein -associated disease from multiple sclerosis at IFN 2023. [WATCH TIME: 5 minutes]
Challenges With Access, Delivery of New ALS Therapeutics: Richard Bedlack, MD, PhD, MS
The director of the Duke ALS Clinic at Duke Health provided perspective on the issues with getting newly approved ALS therapies to patients who need them the most. [WATCH TIME: 4 minutes]
2 Clarke Drive Cranbury, NJ 08512